2023-08-21T14:49:27+08:002022-07-08|Publish|

Impact Factor (IF) is listed based on IF of that year:

  1. Huang JM, Wang XR, Wang ZM, Deng LY, Wang YW, Tang YP#, Luo LX# & Leung EL#. Extracellular vesicles as a novel mediator of interkingdom communication. Cytokine and Growth Factor Reviews. 2023 (accepted) (IF 17.66)
  2. Leung EL#*, Li RZ#, Fan XX#, Wang LY, Wang Y, Jiang ZB, Huang JM, Pan HD, Fan Y, Xu HM, Wang F, Rui HP, Wong P, Sumatoh H, Fehlings M, Nardin A, Gavine P, Zhou LE, Cao YB* and Liu L*. Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy. Nature Communication. 2023 (accepted) (IF 17.7)
  3. Huang JM, Duan FG, Xie C, Xu JH, Zhang YZ, Wang YW, Tang YP* & Leung EL*. Microbes mediated immunogenic cell death in cancer immunotherapy. Immunological Reviews. 2023 (accepted) (IF 10.983)
  4. Wang J, Li RZ, Wang WJ, Pan HD, Xie C, Yau LF, Wang XX, Long WL, Chen RH, Liang TL, Ma LR, Li JX, Huang JM, Wu QB, Liu L#, He JX# and Leung EL#. CERS4 predicts positive anti-PD-1 response and promotes immunomodulation through Rhob-mediated suppression of CD8+Tim3+ exhausted T cells in non-small cell lung cancer. Pharmacological Research. 2023 (accepted) (IF 9.3)
  5. Zhang JH, He JX, Huang JM, Li XF, Fan XQ, Li WB, Wu GF, Xie C, Fan XX, Zhang JM#, Yao XJ#, Wang R# and Leung EL#. Pharmacokinetics, absorption and transport mechanism for ginseng polysaccharides. Biomedicine & Pharmacotherapy. 2023 (accepted) (IF 7.419)
  6. Zhang J, Zhang J, Leung EL and Yao XJ. Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical therapy. Expert Opin Investig Drugs. 2023 Feb 15:1-6. doi: 10.1080/13543784.2023.2178419. Online ahead of print. (IF 5.528)
  7. Zhang J, Liu P, Chen J, Yao D, Liu Q, Zhang J, Zhang HW, Leung EL*, Yao XJ* and Liu L*. Upgrade of Chrysomycin A as a novel Topoisomerase II inhibitor to Curb KRAS-mutant lung adenocarcinoma progression. Pharmacological Research 2023 Jan; 187:106565.doi: 10.101016/j.phrs.2022.106565. Epub 2022 Nov 19 (IF 10.334)
  8. Leung EL, Fan XX, Huang JM, Huang C, Lin H & Cao YB. Holistic immunomodation for small cell lung cancer. Seminar in Cancer Biology 2023 Jan;88:96-105. doi: 10.1016/j.semcancer.2022.11.012. Epub 2022 Dec 5. (IF 17.012)
  9. Xie Y, Feng SL, He F, Yan PY, Yao XJ, Fan XX, Leung EL* and Zhou H*. Down regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer. Pharmacological Research 2022 (accepted). (IF 10.334)
  10. Tu G, Liu Q, Qiu Y, Leung EL* and Yao XJ*. In silico Study of the Acquired Resistance Caused by the Secondary Mutations of KRAS G12C Protein Using Long Time Molecular Dynamics Simulation and Markov State Model Analysis. International Journal of Molecular Sciences. 2022 (accepted) (IF 6.208)
  11. Wang J, Luo ZJ, Lin LZ, Sui XB, Yu LL, Xu C, Zhang RN, Zhao ZM, Zhu QR, An B, Wang Q, Chen B, Leung EL* and Wu QB*. Anoikis-associated lung cancer metastasis: Mechanism and therapies. 2022 (accepted). (IF 6.575)
  12. Cai J, Fan XX, Li RZ, Lin H, Li M, Song Q, Xie C, Wong G, Liu SQ, Cao YB* and Leung EL*. Detection of single cancer cell multi-drug resistance with single cell bioanalyzer. Oncology Letter. 2022 (accepted) (IF 1.554)
  13. Liu Q, Song MH, Qiu Y, Leung EL, Huang Q, Yao XJ. Long-timescale stimulation reveals critical non-conserved residues of phosphodiesterase affecting selectivity of Bay60-7550. Computational and Structural Biotechnology. 2022 (accepted) (IF 7.271)
  14. Fan XQ, Mai CT, Zuo L, Huang JM, Xie C, Jiang ZB, Li RZ, Yao XJ, Fan XX, Wu QB, Yan PY, Liu L, Chen JX*, Xie Y* and Leung EL*. Herbal formula BWBDS alleviates polymicrobial sepsis-induced liver injury via increasing the gut microbiota Lactobacillus johnsonii and regulating macrophage anti-inflammatory activity in mice. Acta Pharmaceutica Sinica B 2023 Mar;13(3):1164-1179. (IF 14.15)
  15. Huang M#, He F#, Li D, Xie YJ, Jiang ZB, Huang JM, Zhao XP, Nasim AA, Chen JH, Hou JC, Fan XM, Leung EL, Fan XX*. PA-MSHA induces inflamed tumor microenvironment and sensitizes tumor to anti-PD-1 therapy. Cell Death & Disease, 2022; 13:391. (IF 9.685)
  16. Wang J, Feng ZX, Ren T, Meng WY, Khan I, Fan XX, Pan HD, Liu L, Tang YJ, Yao XJ, Li RZ, Wang MF*, Leung EL*. Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor. Medicine, 2022; 101(41): e31027. ( IF 1.817)
  17. Leung EL*#, Huang JM#, Zhang JM#, Zhang JH, Wang MF, Zhu YZ, Meng ZQ, Yu HJ, Neher E, Ma LJ *, Yao XJ*. Novel anticancer strategy by targeting the gut microbial neurotransmitter signaling to overcome immunotherapy resistance. Antioxidants and Redox Signaling. 2022 Aug 26 doi: 10.1089/ars.2021.0243.Online ahead of print (IF 7.468).
  18. Wu C, Chen J, Leung EL, Chang H, Wang X. Editorial: Artificial Intelligence in Traditional Medicine. Frontiers in Pharmacology, 2022; 13:933133. ( IF 5.988)
  19. Cai J, Zhang LC, Zhao RJ, Pu LM, Chen KY, Nasima AA, Leung EL* and Fan XX*. Chelerythrine ameliorates rheumatoid arthritis by modulating the AMPKmTORULK-1 signaling pathway. Phytomedicine, 2022, 104; 154140 (IF 5.34)
  20. Li RZ, Wang XR, Wang J, Xie C, Wang XX, Pan HD, Meng WY, Liang TL, Li JX, Yan PY, Wu QB, Liu L*, Yao XJ* and Leung EL*. The key role of sphingolipid metabolism in cancer: New therapeutic targets, diagnostic and prognostic values, and anti-tumor immunotherapy resistance. Frontier in Oncology. 2022 (accepted). (IF 5.738)
  21. Wang YQ, Chen MT, Yu H, Yuan G, Luo L, Xu XF, Xu YN, Sui XB, Leung EL* and Wu QB*. The role and mechanism of action of natural compounds in the prevention and treatment of cancer and cancer metastasis. Frontier in Bioscience Landmark. 2022, 27(6), 192; https://doi.org/10.31083/j.fbl2706192 (IF 4.009)
  22. Wei CL, Khan MA, Du JM, Cheng JL, Tania M, Leung EL* and Fu JJ*. Cordyceptin inhibits triple-negative breast cancer cell migration and invasion by regulating EMT-TFs SLUG, TWIST1, SNAIL1, and ZEB1. Frontier in Oncology 14 June 2022 https://doi.org/10.3389/fonc.2022.898583 (IF 6.244)
  23. Xie YJ, Huang M, Li D, Hou JC, Liang HH, Nasim AA, Huang JM, Xie C, Leung EL* and Fan XX*. Bacteria-based nanodrug for anticancer therapy. Pharmacol Res 2022;182: 106282 (IF 7.658)
  24. Wang J, Jiang M, Xiong A., Zhang L, Luo, L, Liu Y, Liu S, Ran Q, Wu D, Xiong Y, He X*, Leung EL* and Li G*. Integrated Analysis of Single-Cell and Bulk RNA Sequencing Reveals Pro-Fibrotic PLA2G7(High) Macrophages in Pulmonary Fibrosis. Pharmacol Res 2022;182, 106286 (IF 7.658)
  25. Xiong Q, Wan AT, Liu X, Fung CS, Xiao XJ, Malainua N, Hou JP, Wang LY, Wang MQ, Yan KY, Cui YB, Leung EL, Nong WY, Shin SK, Au SW, Jeong KY, Chew FT, Hui JH, Leung TF, Tungtrongchitr A, Zhong NS, Liu ZG, Tsui KW. Comparative genomics reveals insights into the divergent evolution of astigmatic mites and household pest adaptations. Mol Biol. Evol 2022 May 10; msac097 doi:1093/molbev/msac097. Online ahead of print. (IF 16.24)
  26. Li JX, Li RZ, Ma LR, Wang P, Xu DH, Huang J, Li LQ, Tang L, Xie Y, Leung EL* and Yan PY* Targeting mutant Kirsten Rat Sarcoma Viral oncogene homolog in non-small cell lung cancer: current difficulties, integrative treatments and future perspectives. Frontiers in Pharmacology. April 2022 https://doi.org/10.3389/fphar.2022.875330 (IF 5.81)
  27. Liu J, Zhuang Y, Wu J, Wu Q, Liu M, Zhao Y, Liu Z, Wang C, Lu L, Meng Y, Lei K, Li X, Wu Q, Leung EL, Guo Z, Liu L, Li T. IKKβ mediates homeostatic function in inflammation via competitively phosphorylating AMPK and IκBα. Acta Pharmaceutica Sinica B, 2022; 12(2):651-664. (IF 14.903)
  28. Cao KY, Yan TM, Zhang JZ, Chan TF, Li J, Li C, Leung EL, Gao J, Zhang BX, Jiang ZH. A TRPA1 tRNA-derived fragment from Chinese yew suppresses ovarian cancer growth via targeting. Molecular Therapy-Nucleic Acids, 2022; 27:718-732. (IF 10.183)
  29. Wang XR, Jiang ZB, Xu C, Meng WY, Liu P, Zhang YZ, Xie C, Yu JY, Xie YJ, Liang TL, Yan HX, Fan XX, Yao XJ*, Wu QB* and Leung EL*. Andrographolide suppresses non-small-cell lung cancer progression through induction of autophagy and antitumor immune response. Pharmacol Res. 2022;179:106198.doi: 10.1016/j.phrs.2022.106198. Epub 2022 Mar 31 (IF 7.658)
  30. Zheng LG, Tan Y, Hu YC, Shen JT, Qu ZP, Chen XB, Ho CL, Leung EL, Zhao W and Dai L. CRISPR/Cas-based genome editing for human gut commensal bacteroides species. ACS Synth Biol. 2022 Jan 21;11(1):464-472.doi: 10.1021/acssynbio.1c00543. Epub 2022 Jan 6. (IF 5.249)
  31. Zhang JM*, Zhang JH*, Liu Q, Fan XX, Leung EL#, XJ Yao# and Liang Liu#. Resistance looms for KRAS G12C inhibitors and rational tackling strategies. Pharmacology and Therapeutics. 2022 Jan;229:108050. doi: 10.1016/j.pharmthera.2021.108050. Epub 2021 Dec 3. (IF 11.13)
  32. Li KS*, Cheng HB*,Shen WX*, Leung EL, Le S, Yu LL, Xie H, Sui HB*, Zhu XM* and Wu QB*. Compound Taxus Chinensis capsule combined with chemotherapy for non-small-cell lung cancer: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials. Evidence-Based Complementary and Alternative Medicine. 2021 (in press) (IF: 2.629)
  33. Hu W, Zhang J, Wang M, Chen W, Chai L, Leung EL, Tang Y. Clinical Features and Risk Factors Analysis for Hemorrhage in Adults on ECMO. Frontiers in Medicine, 2021; 8:731106. ( IF 5.058)
  34. Wang Y, Guo Y, Qiang S, Jin R, Li Z, Tang Y, Leung EL, Guo H, Yao X. 3D-QSAR, Molecular Docking, and MD Simulations of Anthraquinone Derivatives as PGAM1 Inhibitors. Frontiers in Pharmacology, 2021; 12:764351. ( IF 5.988)
  35. Wang Q, Zhang Q, Leung EL, Chen Y, Yao X. Exploring the thermodynamic, kinetic and inhibitory mechanisms of 5-iTU targeting mitotic kinase haspin by integrated molecular dynamics. Physical Chemistry Chemical Physics, 2021; 2021(23):18404-18413. ( IF 3.945)
  36. Zhang RN, Pan T, Xiang Y, Zhang MM, Xie H, Liang ZM, Chen B, Xu C, Wang J, Huang XX, Zhu QR, Zhao ZM, Gao Q, Wen CY, Liu WC, Ma WR, Feng J, Sun XN, Duan T, Leung EL, Xie T* , Wu QB* and Sui XB* Curcumenol triggered ferroptosis in lung cancer cells via lncRNA H19/ miR-19b-3p/FTH1 axis. Bioactive materials. 2021 (In press) (IF 14.593)
  37. Liang TL, Li RZ, Mai CT, Guan XX, Li JX, Wang XR, Ma LR, Zhang FY, Wang J, He F, Pan HD, Zhou H, Yan PY, Fan XX, Wu QB, Neher E, Liu L, Xie Y*, Leung EL* and Yao XJ*. A method establishment and comparison of in vivo lung cancer model development platforms for evaluation of tumour metabolism and pharmaceutical efficacy. Phytomedicine. 2021 (accepted) (IF 5.34)
  38. Zhang FY, Li RZ, Xu C, Fan XX, Li JX, Meng WY, Wang XR, Liang TL, Guan XX, Pan HD, Liu L, Yao XJ*, Wu QB* and Leung EL*. Emodin induces apoptosis and suppresses non-small-cell lung cancer growth via downregulation of sPLA2-IIa. Phytomedicine. 2021 (accepted) (IF 5.34)
  39. Liu Q, Wang YW, Leung EL and Yao XJ. In silicostudy of intrinsic dynamics of full-length apo-ACE2 and RBD-ACE2 complex. Comput Struct Biotechnol J. 2021;19:5455-5465. doi: 10.1016/j.csbj.2021.09.032. Epub 2021 Sep 29. (IF 7.271)
  40. Wang QQ, Shao XM, Leung EL, Chen YQ, Yao XJ. Selectively targeting individual bromodomain: Drug discovery and molecular mechanisms. Pharmacol Res. 2021 Oct; 172:105804. doi: 10.1016/j.phrs.2021.105804. Epub 2021 Aug 25. (IF 7.658)
  41. Deng JH, Han JD, Chen JH, Zhang YM, Huang QJ, Wang Y, Qi XX, Liu ZQ, Leung EL, Wand DW, Feng Q and Lu LL. Comparison of analgesic activities of aconitine in different mice pain models. PLoS One. 2021 Apr 1;16(4):e0249276.doi: 10.1371/journal.pone.0249276. eCollection 2021. (IF= 3.24)
  42. Wu Z, Zhu M, Kang Y, Leung EL, Lei T, Shen C, Jiang D, Wang Z, Cao D, Hou T. Do we need different machine learning algorithms for QSAR modeling? A comprehensive assessment of 16 machine learning algorithms on 14 QSAR data sets. Briefing in Bioinformatics. 2021 Jul 20;22(4):bbaa321. doi: 10.1093/bib/bbaa321. (IF=11.622)
  43. Zhong ZH, Yi ZL, Zhao YD, Wang J, Jiang ZB, Xu C, Xie YJ, He QD, Yong ZY, Yao XJ, Leung EL, Coghi PS, Fan XX and Chen M. Pyronaridine induces apoptosis in non-small cell lung cancer cells by upregulating death receptor 5 expression and inhibiting epidermal growth factor receptor. Chem Biol Drug Des. 2021 Jul 21. doi: 10.1111/cbdd.13926. Online ahead of print. (IF=2.817)
  44. Bai SS, Cu SN, Wen WH, Leung EL, Bai J, Lin HY, Cui YF, Yang L, Liu ZQ, Zheng Y and Zhang R. Tanshinone IIA suppresses non-small cell lung cancer through Beclin-1-mediated autophagic apoptosis. Engineering. 2021 (accepted) (IF=7.553)
  45. Ma LR, Li JX, Tang L, Li RZ, Yang JS, Sun O, Leung EL* and Yan PY*. Immune checkpoints and immunotherapy in non-small cell lung cancer (NSCLC): novel study progression, challenges and solutions. Oncology Letters. 2021 (accepted). (IF=2.967)
  46. Jiang ZB*, Wang WJ*, Xu C*, Xie YJ, Wang XR, Zhang YZ, Huang JM, Huang M, Xie C, Liu P, Fan XX, Ma YP, Yan PY, Liu L, Yao XJ*, Wu QB*, and Leung EL*. Luteolin and its derivatives apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer. Cancer Letter. 2021 Sep 1; 515:36-48.doi: 10.1016/j.canlet.2021.05.019. Epub 2021 May 28. (IF=8.679)
  47. Huang JM*, Liu D*, Wang YW*, Liu L, Li J, Yuan J, Jiang ZH, Jiang ZB, Hsiao WL, Liu HZ, Khan I, Xie Y, Wu JL, Xie YJ, Zhang YZ, Fu Y, Liao JY, Wang WJ, Lai HL, Shi AX, Cai J, Luo LX, Li RZ, Yao XJ, Fan XX, Wu QB, Liu ZQ, Yan PY, Lu JG, Yang MR, Wang L, Cao YB#, Wei H# & Leung EL#. Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the anti-tumor effect of anti-programmed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy. 2021. May 18:gutjnl-2020-321031. doi: 10.1136/gutjnl-2020-321031. (IF= 31.795; ESI highly cited paper)
  48. Song Q#, He X#, Xiong Y#, Wang JL, Zhang L,  Leung EL*, GP Li*. The functional landscape of Golgi membrane protein 1 (GOLM1) phosphoproteome reveal GOLM1 regulating P53 that promotes malignancy. Cell Death Discovery. 2021 Mar 1;7(1):42. doi: 10.1038/s41420-021-00422-2. (IF=5.241)
  49. Jiang ZB, Xu C, Wan WJ, Zhang YZ, Huang JM, Xie YJ, Wang QQ, Fan XX, Yao XJ, Xie C, Wang XR, Yan PY, Ma YP*, Wu QB* and Leung EL*. Plumbagin suppresses non-small cell lung cancer progression through downregulating ARF1 and by elevating CD8+ T cells. Pharmacological Research. 2021 Jul;169:105656.doi: 10.1016/j.phrs.2021.105656. Epub 2021 May 6 (IF=7.658)
  50. Chen HH#, Meng WY#, Li RZ#, Wang QY, Wang YQ, Pan HD, Yan PY, Wu QB, Liu L, Yao XJ*, Kang M* and Leung EL*. Potential prognostic factors in progression-free survival for patients with cervical cancer. BMC Cancer. 2021 May 10;21(1):531.doi: 10.1186/s12885-021-08243-3  (IF=4.43)
  51. Li JX, Li RZ, Sun A, Zhou H, Yang JS, Huang JM, Zhang YZ, Jiang ZB, Liang TL, Ma LR, Wang J, Wang XR, Fan XQ, Huang J, Tang L*, Leung EL* and Yan PY*. Metabolomics and integrated network pharmacology analysis reveal Tricin as the active anti-cancer component of Weijing decoction by suppression of PRKCA and sphingolipid signaling. Pharmacological Research. 2021 Sep;171:105574.doi: 10.1016/j.phrs.2021.105574. Epub 2021 Jul 25 (IF=7.658)
  52. Zhang FY, Li RZ, Li JX, Fan XX, Liu L, Yao XJ* and Leung EL*. Phospholipase A2 as a novel therapeutic target in lung cancer. Integrative Cancer Science and Therapeutics. 2020 doi:10.15761/ICST.1000349 (non-SCI)
  53. Shen C, Weng GQ, Zhang XJ, Leung EL, Yao XJ, Pang JP, Chai X, Li D, Wang EC, Cao DS,  Hou Accuracy or novelty: what can we gain from target-specific machine-learning-based scoring functions in virtual screening? Brief Bioinform. 2021 Jan8; bbaa410 doi: .101093/bib/bbaa410. (IF=11.622)
  54. Wang J, Xu C, Chen Y, Le S, Li T, Fan XX, Yu LL, Zhang RN, Chen B, Chen HW, Sui XB*, Leung EL* and WU QB*. b-elemene enhances the antitumor activity of erlotinib by inducing apoptosis through AMPK and MAPK pathways in TKI-resistant H1975 lung cancer cells. J of Cancer. 2021 Feb 22;12(8):2285-2294. doi: 10.7150/jca.53382. eCollection 2021. (IF=4.207)
  55. Jiang ZB, Huang JM, Xie YJ, Zhang YZ, Chan C, Lai HL, Wang WJ, Yao XJ, Fan XX, Wu QB, Xie C, Wang MF*, Leung EL*. Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MC1-C/PD-L1 axis. Journal of Experimental & Clinical Cancer Research. 2020 Nov 19;39(1):249.doi: 10.1186/s13046-020-01741-5 (IF= 161)
  56. Lai HL#, Fan XX#, Li RZ#, Wang YW, Zhang JM, Liu L, Hou TJ, Neher E, Yao XJ* and Leung EL*. Roles of ion fluxes, metabolism, and redox balance in cancer therapy. Antioxidants and redox signaling. 2021 May 10;34(14):1108-1127.doi: 10.1089/ars.2020.8125. Epub 2020 Dec 3. (IF=8.401)
  57. Wang YW, Tang S, Lai HL, Jin RY, Long X, Li N, Tang YP, Guo H, Yao XJ* & Leung EL*. Discovery of novel IDH1 inhibitor through comparative structure-based virtual screening. Front Pharmacol. 2020 Nov 11;11:579768. doi: 10.3389/fphar. eCollection 20 (IF= 225)
  58. Xie Y#, Meng WY#, Li RZ#, Wang YW, Qian X, Chan C, Yu ZF, Fan XX, Pan HD, Xie C, Wu QB, Yan PY, Liu L, Tang YJ, Yao XJ*, Wang MF* and Leung EL*. Early lung cancer diagnostic biomarker discovery by machine learning methods. Translational Oncology. 2021 Jan;14(1):100907.doi: 10.1016/j.tranon.2020.100907. Epub 2020 Nov 17. (IF= 558)
  59. Liu Y#, Wang MF#, Luo GS, Qian X, Wu CL, Zhang YZ, Chen BY, Leung EL* and Tang YJ*. Experience of N-acetylcysteine airway management in the successful treatment of one case of critical condition with COVID-19. Medicine. October 16, 2020 Vol 99(42):pe22577 doi: 10.1097/MD.0000000000022577 (IF= 1.552)
  60. Zhang YZ#, Lai HL#, Chen PP#, Li D, Khan I, Hsiao WL, Fan XX, Yao XJ, Wu QB*, Wang MF* & Leung EL*. Clinical significance of LSECtin and its association with PVR in non-small-cell lung cancer patients. Annals of Translational Medicine. 2020 Nov;8(21):1393.doi: 10.21037/atm-20-3665 (IF= 297)
  61. Wu QB*, Yao XJ, Chen HW, Li T, Fan XX, Zhang GL, Yu LL, Chen M, Xu C, Zhang RN, Chen B, Sui XB*, Leung EL*. Long-term aspirin use for primary cancer prevention: An updated systematic review and subgroup meta-analysis of 29 randomized clinical trials. Cancer.2020 Sep 14;11(21):6460-6473.doi: 10.7150/jca.49001. eCollection 2020 (IF= 3.565)
  62. Leung EL#, Lai HL#, Li RZ, Pan HD, Jiang ZB Li Y, Duan FG, Xu JH, Zhang YZ, Shi AX, Wei CL, Zhang FY, Yao XJ and Liang Liu. Roles of serum amyloid A1 protein isoforms in rheumatoid arthritis. Engineering. 2020 (In press). (IF= 495)
  63. Leung EL* & Xu SW*. Traditional Chinese Medicine in cardiovascular drug discovery. Pharmacol Res. 2020 Aug 24;160:105168. doi: 10.1016/j.phrs.2020.105168. (IF= 5.893)
  64. Liu HT, Zheng JP, Lai HC, Hu BF, Zhu L, Leung EL* & Wei H*. Microbiome technology empowers the development of traditional Chinese medicine. Science China Life Science. 2020 Aug 7. Doi:10.1007/s11427-020-1778- (IF= 4.611)
  65. Leung EL, Pan HD, Huang YF, Fan XX, Wang WY, He F, Cai J, Zhou H* & Liu L*. The scientific foundation of Chinese herbal medicine against COVID-19. 2020 Oct;6(10):1099-1107.doi: 10.1016/j.eng.2020.08.009. Epub 2020 Sep 5 (IF= 6.495)
  66. Wang WJ, Mao LF, Lai HL, Wang YW, Jiang ZB, Li W, Huang JM, Xie YJ, Xu C, Liu P, Li YM*, Leung EL* & Yao XJ*. Dolutegravir Derivative Inhibits Proliferation and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Calcium Signaling Pathway. Pharmacol Res. 2020 Nov;161:105129.doi: 10.1016/j.phrs.2020.105129. Epub 2020 Aug 9 (IF= 5.893)
  67. Hussain S, Xie YJ, Li D, Malik SI, Hou JC, Leung EL* & Fan XX*. Current strategies against COVID-19. Chinese Medicine. 15, Article number: 70 (2020) (IF= 2.96)
  68. Chen B, Zhang RN, Fan XX, Wang J, Xu C, An B, Wang Q, Wang J, Leung EL*, Sui XB* and Wu QB*. Clinical diagnostic value of long non-coding RNAs in Colorectal Cancer: A systematic review and meta-analysis. Journal of Cancer. 2020 Jul 11; 11(18): 5518–5526.2020 doi: 7150/jca.46358 (IF= 3.565)
  69. Luo SD*, Xu JH*, Jiang ZB*, Liu L, Wu QB#, Leung EL# & Leung P#. Artificial intelligence-based collaborative filtering method with ensemble learning for personalized lung cancer medicine without genetic sequencing. Pharmacol Res. Oct 2020 https://doi.org/10.1016/j.phrs.2020.105037 (IF= 5.893)
  70. Huang JM*, Jiang ZB*, Wang YW*, Fan XJ, Cai J, Yao XJ, Liu L, Huang J, He JX, Xie C, Wu QB#, Cao YB# & Leung EL#. Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy. Current Opinion in Pharmacology. 2020 Jun 30;54:1-10. doi: 10.1016/j.coph.2020.06.004. (IF=4.807)
  71. Huang FF, Li Y, Leung EL, Liu XH, Liu KF, Wang Q, Lan YQ, Li XL, Yu HB, Cu L, Luo H, Luo LX*. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). Pharmacol Res. 2020 Aug;158:104929. doi: 10.1016/j.phrs.2020.104929. (IF=5.893)
  72. Xie YJ#, Gao WN#, Wu QB, Yao XJ, Jiang ZB, Wang YW, Wang WJ, Li W, Hussain S, Liu L*, Leung EL* & Fan XX*. Chelidonine Selectively Inhibits the Growth of Gefitinib-resistant Non-small Cell Lung Cancer Cells through the EGFR-AMPK Pathway. Pharmacol Res. 2020 Sep;159:104934. doi: 10.1016/j.phrs.2020.104934. Epub 2020 May 25. (IF=5.893)
  73. Zheng Y, Xiong C, Liu Y, Qian X, Tang Y, Liu L, Leung EL* and Wang MF*. Epidemiological and clinical characteristics analysis of COVID-19 in the surrounding areas of Wuhan, Hubei province in 2020. Pharmacol Res. 2020 Apr 30;157:104821. doi: 10.1016/j.phrs.2020.104821. [Epub ahead of print] (IF=5.893)
  74. You H, Zhang YZ, Lai HL, Li D, Lu YQ, Li RZ, Khan I, Hsiao WL, Duan FG, Fan XX, Yao XJ, Cao YB, Wu QB*, Leung EL* and Wang MF*. Prognostic significance of tumor poliovirus receptor and CTLA4 expression in patients with surgically resected non-small-cell lung cancer. J Cancer Res Clin Oncol. 2020 Jun;146(6):1441-1450. doi: 10.1007/s00432-020-03189-8. Epub 2020 Apr 4. (IF=3.656)
  75. Fan XX, Xu MZ, Leung EL, Cai J, Yuen Z* and Liu L*. ROS-responsive Berberine polymeric micelles effectively suppressed the inflammation of rheumatoid arthritis by targeting mitochondria.  Nano-Micro Letters. 2020 Mar 20;12(1):76.doi: 10.1007/s40820-020-0410-x  (IF=12.264)
  76. Song Q, Zhang J, Wu QB, Li GP* & Leung EL*. Kanglaite injection plus Fluorouracil-based chemotherapy on the reduction of adverse effects and improvement of clinical effectiveness in patients with advanced malignant tumors of the digestive tract: A meta-analysis of 20 RCTs following the PRISMA guidelines. Medicine. 2020 Apr;99(17):e19480.doi: 10.1097/MD.0000000000019480 (IF=1.552)
  77. Mok SW, Wong VK, Lo HH, de Seabra Rodrigues Dias IR, Leung EL, Law BY, Liu L. Natural products-based polypharmacological modulation of the peripheral immune system for the treatment of neuropsychiatric disorders. Pharmacology & Therapeutics. 2020 Jan 21:107480. doi: 10.1016/j.pharmthera.2020.107480. [Epub ahead of print] (IF=10.557)
  78. Wang ZH, Wu WB, Guan XC, Guo S, Li CW, Niu RX, Gao J, Jiang M, Bai LP, Leung EL, Hou YY, Jiang ZH & Bai G. 20(s)-protopanaxatriol promotes the binding of P53 and DNA to regulate the antitumor network. Acta Pharmaceutica Sinica B. 2020 Jun;10(6):1020-1035. doi: 10.1016/j.apsb.2020.01.017. Epub 2020 Feb 5. (IF=7.097)
  79. Ying Liu, Xi Chen, Leung EL and Jiang Chen. GORAB promotes embryonic lung maturation through antagonizing AKT phosphorylation, versican expression and mesenchymal cell migration. The FASEB Journal. 2020 Apr;34(4):4918-4933.doi: 10.1096/fj.201902075R. Epub 2020 Feb 18. (IF=4.966)
  80. Xu C, Yao XJ, Li T, Wang J, Sue XB, Leung EL* and Wu QB*. Pretreatment neutrophil-to-lymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR-mutant non-small cell lung cancer. Translational Cancer Research. 2020 Apr Vol 9, No 4 (IF=0.986)
  81. Leung EL* & Wu QB*. A commentary on “Insomania and risk of mortality form all-cause, cardiovascular disease, and cancer: Systematic review and meta-analysis of prospective cohort studies. Sleep Medicine Reviews. 2019 Dec;48:101215.doi: 10.1016/j.smrv.2019.101215. Epub 2019 Sep 24. (IF= 517)
  82. Yan LE, Zhang HY, Wada M, Fang L, Feng J, Zhang WL, Chen Q, Cao YZ, Pinz KG, Chen KH, Petrov JC, Chen X, Leung EL, Fan XX, Senzel L, Jiang X, Ma YP. Targeting two antigens associated with B-all with CD19-CD123 compound CART cell therapy. Stem Cell Reviews and Reports. 2020 Apr;16(2):385-396.doi: 10.1007/s12015-019-09948-6 (IF= 316)
  83. Chen HW, Yao XJ, Li T, Lam CWK, Zhang RN, Zhang HX, Wang J, Zhang W, Leung EL* & Wu QB*. Compound Kushen injection combined with platinum-based chemotherapy for stage III/V non-small cell lung cancer: A meta-analysis of 37 RCTs following the PRISMA guidelines. Medicine (Baltimore). 2019 Dec;98(52):e18552. doi: 10.1097/MD.0000000000018552. (IF= 565)
  84. Leung EL* & QB Wu*. A commentary on “Association of dietary fiber and yogurt consumption with lung cancer risk: a pooled analysis. JAMA Oncology. 2020 Mar 19. doi: 10.1001/jamaoncol.2020.0261. [Epub ahead of print] (IF= 799)
  85. Leung EL* & QB Wu*. Letter to the editors: The evidence strength of a meta-analysis of aspirin for primary prevention of cancer. Journal of Cancer Research and Clinical Oncology. 2020 Aug;146(8):2173-2175. doi: 10.1007/s00432-019-03069-w (IF= 332)
  86. Li JX, Huang JM, Jiang ZB, Li RZ, Sun A, Leung EL* & Yan PY*. Current clinical progress of PD-1/PD-L1 immunotherapy and potential combination treatment in non-small cell lung cancer. Integrative Cancer Therapeutics. Jan-Dec 2019; 18:1534735419890020.doi: 10.1177/1534735419890020. (IF= 634)
  87. Duan FG#, Wang MF#, Cao YB, Li D, Li RZ, Fan XX, Khan I, Lai HL, Zhang YZ, Hsiao WL, Yao XJ, WU QB, Liu L*, Tang YJ* & Leung EL*. MicroRNA-421 confers paclitaxel resistance by binding to the KEAP1 3’UTR and predicts poor survival in non-small cell lung cancer. Cell Death and Disease. 2019 Oct 28;10(11):821. doi: 10.1038/s41419-019-2031-1. (IF= 959)
  88. Wang YW, Tang CP, Yao S, Lai HL, Li RZ, Xu JH, Wang QQ, Fan XX, Wu QB, Leung EL*, Ye Y* & Yao XJ*. Discovery of a novel protein kinase C activator from Croton tiglium for inhibition of non-small cell lung cancer. Phytomedicine. 2019 Sep 27;65:153100. doi: 10.1016/j.phymed.2019.153100. [Epub ahead of print] (IF= 18)
  89. Chen HW, Yao XJ, Li T, Xu C, Wang J, Sui XB, Leung EL* & Wu QB*. Long-term aspirin use for cancer primary prevention: A protocol for updated systematic review and subgroup meta-analysis of randomized clinical trials. Medicine. 2019 Sep;98(39):e17382. doi: 10.1097/MD.0000000000017382. (IF= 87)
  90. Ren T#, Fan XX#, Wang MF#, Duan FG, Wei CL, Li RZ, Jiang ZB, Wang YW, Yao XJ, Chen MW*, Tang YJ*, Leung EL*. Oncogenic role of MiR-20b is mediated by a positive feedback loop of Wnt/beta;-catenin pathway in non-small cell lung cancer. International Journal of Oncology. 2020 Feb;56(2):470-479. doi: 10.3892/ijo.2019.4940. Epub 2019 Dec 13. (IF= 571)
  91. Chen HW#, Yao XJ#, Liu ZT, Li T, Xu C, Wang J, Sui XB, Leung EL* & Wu QB*. Efficacy and safety of Shenqi Fuzheng injection combined with platinum-based chemotherapy for stage III/IV non-small cell lung cancer: A protocol for systematic review and meta-analysis of randomized controlled trials. Medicine. 2019 Sep;98(39):e17350. doi: 10.1097/MD.0000000000017350. (IF= 87)
  92. Zhang YZ, Han CY, Duan FG, Fan XX, Yao XJ, Parks RJ, Tang YJ, Wang MF, Liu L, Tsang BK* & Leung EL*. p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling. Cancer Cell Int. 2019 Jul 19;19:188. doi: 10.1186/s12935-019-0910-2. eCollection 2019. (IF= 439)
  93. Pan H, Guo R, Ju Y, Wang Q, Zhu J, Xie Y, Zheng Y, Li T, Liu Z, Lu L, Li F, Tong B, Xiao L, Xu X, Leung EL, Li R, Yang H, Wang J, Zhou H, Jia H, Liu L. A single bacterium restores the microbiome dysbiosis to protect bones from destruction in a rat model of rheumatoid arthritis. Microbiome. 2019 Jul 17;7(1):107. doi: 10.1186/s40168-019-0719-1. (IF= 465)
  94. Jin N, Bi AW, Lan XJ, Xu J, Wang XM, Liu YL, Wang T, Tang S, Zeng HL, Chen ZQ, Tan MJ, Ai J, Xie H, Zhang T, Liu DD, Huang RM, Song Y, Leung EL, Yao XJ, Ding J, Geng MY, Lin SH*, and Huang M*. Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer. Nature Communication. 2019 Jun 20;10(1):2701. doi: 10.1038/s41467-019-10427-2. (IF= 878)
  95. Zhang J, Yang C, Wei D, Li H, Leung EL, Deng Q, Liu Z, Fan XX, Zhang Z. Long-term efficacy of Chinese medicine Bushen Capsule on cognition and brain activity in patients with amnestic mild cognitive impairment. Pharmacol Res. 2019 Jun 17:104319. doi: 10.1016/j.phrs.2019.104319. [Epub ahead of print] (IF= 574)
  96. Tian GH, Wu CH, Li J, Liang BL, Zhang FL, Fan XX, Li ZW, Wang YJ, Li ZH, Li D, Leung EL* & Chan JX*. Network pharmacology based investigation into the effect mechanism of modified Sijunzi decoction against the subtypes of chronic atrophic gastritis. Pharmacol Res 2019 Jun;144:158-166. doi: 10.1016/j.phrs.2019.04.012. Epub 2019 Apr 13. (IF= 574)
  97. Xu JH#, Wang QQ#, Leung EL#, Li Y, Fan XX, Wu QB*, Yao XJ* & Liu L*. Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin remodeling factor in non-small cell lung cancer. Frontiers of Medicine. 2019 May 18. doi: 10.1007/s11684-019-0694-8. [Epub ahead of print]. (IF= 847)
  98. Wei CL, Zhang DZ, Cheng JL, Chen X, Fan XX, Yao XJ, Wang YW, Jiang ZB, Fu JZ* and Leung EL*. Cordycepin Inhibits Drug-resistance Non-small Cell Lung Cancer Progression by Activating AMPK Signaling Pathway. Pharmacol Res. 2019 Jun;144:79-89. doi: 10.1016/j.phrs.2019.03.011. Epub 2019 Apr 8. (IF= 574)
  99. Leung EL#, Luo LX#, Li Y, Liu ZQ, Li LL, Shi DF, Xie Y, Huang M, Lu LL, Duan FG, Huang JM, Fan XX, Yuan ZW, Ding J, Yao XJ*, Ward DC* & Liu L*. Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant non-small cell lung cancer. 2019. Inter J Cancer 2019 Feb 20. doi: 10.1002/ijc.32222. [Epub ahead of print] (IF= 982)
  100. Leung EL* & Wu QB*. Concurrent use of herbal products with prescription drugs is a double-edged sword and evidence-based medicine contributes to reshaping the practice. Pharmacol Res. 2019 Jan 17. pii: S1043-6618(19)30088-X. doi: 10.1016/j.phrs.2019.01.033. [Epub ahead of print] (IF= 574)
  101. Pan HD, Xiao Y, Wang WY, Ren RT, Leung EL* & Liu L*. Traditional Chinese Medicine as a Treatment for Rheumatoid Arthritis-From Empirical Practice to Evidence-based Therapy. 2018. . (IF=4.568)
  102. Wang QQ, Xu JH, Wang YW, Liu L*, Leung EL* and Yao XJ*. Computational study on the selective inhibition mechanism of MS402 to the first and second bromodomains of BRD4. Protein: Structure, Function, and Bioinformatics. 2019 Jan;87(1):3-11. doi: 10.1002/prot.25611. Epub 2018 Nov 13. (IF=2.501)
  103. Wang QQ, An X, Wang YW, Liu L*, Leung EL* and Yao XJ*. Classical molecular dynamics and metadynamics simulations decipher the mechanism of CBP30 selectively inhibiting CBP/p300 bromodomains. Org Biomol Chem. 2018 Aug 30. doi: 10.1039/c8ob01526k. [Epub ahead of print] (IF=3.49)
  104. Lai HL, Wang YW, Li Y, Jiang ZB, Duan FG, Luo LX, Liu L*, Leung EL* and Yao XJ*. Krukovine suppresses KRAS-mutated lung cancer cell growth and proliferation by inhibiting the RAF-ERK pathway and inactivating AKT. Frontier in Pharmacology. 2018 Aug 22;9:958. doi: 10.3389/fphar.2018.00958. eCollection 2018. (IF=3.831)
  105. Fan XX#, Pan HD#, Guo RJ, Leung EL* & Liang Liu*. Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and redox capacity. Pharmacology and Therapeutics 2018 Jun 25. pii: S0163-7258(18)30112-8. doi: 10.1016/j.pharmthera.2018.06.010. [Epub ahead of print] (IF=10.376)
  106. Wang YW, Lai HL, Fan XX, Luo LX, Duan FG, Jiang ZB, Wang QQ, Leung EL*, Liu L*, Yao XJ*. Gossypol inhibits non-small cell lung cancer cells proliferation by targeting EGFRL858R/T790M. Frontier in Pharmacology. 2018 Jul 9;9:728. doi: 10.3389/fphar.2018.00728. eCollection 2018. (IF=3.831)
  107. Wei CL, Yang LS, Imani S, Fu SY, Lv Hongbin, Li YM, Chen R, Leung EL* & Fu JJ*. Novel homozygous variant of GPR98 causes usher syndrome type IIC in a consanguineous Chinese family by next generation sequencing. BMC Medical Genetics. 2018 Jun 11;19(1):99. doi: 10.1186/s12881-018-0602-0. (IF=1.913)
  108. Li RZ#, Fan XX#, Duan FG, Jiang ZB, Pan HD, Luo LX, Zhou YL, Li Y, Yao YJ, Leung EL* & Liu L*. Proscillaridin A induces apoptosis and suppresses non-small cell lung cancer tumor growth via calcium-induced DR4 up-regulation. Cell Death Dis. 2018 Jun 13;9(6):696. doi: 10.1038/s41419-018-0733-4. (IF=5.638)
  109. Li RZ, Fan XX, Shi DF, Zhu GY, Wang YW, Luo LX, Pan HD, Yao XJ*, Leung EL* & Liu L*. Identification of a new Pyruvate kinase M2 isoform (PKM2) activator for the treatment of non-small cell lung cancer (NSCLC). Chemical Biology & Drug Design. 2018 Jun 21. doi: 10.1111/cbdd.13354. [Epub ahead of print] (IF=2.328)
  110. Dai X, Li RZ, Jiang ZB, Wei CL, Luo LX, Yao XJ, Li GP* & Leung EL*. Honokiol inhibits proliferation, invasion and induces apoptosis through targeting Lyn kinase in human lung adenocarcinoma cells. Frontier in Pharmacology 2018 May 28;9:558. doi: 10.3389/fphar.2018.00558. eCollection 2018. (IF=3.831)
  111. Wang QQ, Xu JH, Li Y, Huang JM, Jiang ZB, Wang YW, Liu L*, Leung EL* and Yao XJ*. Identification of a novel protein arginine methyltransferase 5 inhibitor in non-small cell lung cancer by structure-based virtual screening. Frontier in Pharmacology 2018 Mar 1;9:173. doi: 10.3389/fphar.2018.00173. eCollection 2018. (IF=3.831)
  112. Chen KH, Wada M, Pinz KG, Liu H, Shuai X, Chen X, Yan LE, Petrov JC, Salman H, Senzel L, Leung EL, Jiang X and Ma YP. A compound chimeric antigen receptor strategy for targeting multiple myeloma. Leukemia 2018 Feb;32(2):402-412. doi: 10.1038/leu.2017.302. Epub 2017 Sep 27. (IF=10.023)
  113. Leung EL#, Luo LX#, Liu ZQ, Wong VKW, Lu LL, Xie Y, Zhang N, Qu YQ, Fan XX, Li Y, Huang M, Xiao DK, Huang J, Zhou YL, He JX, Ding J, Yao XJ, Ward DC, Liu L. Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity. Cell Death Dis. 2018 Feb 13;9(2):216. doi: 10.1038/s41419-017-0065-9. (# co-first author) (IF=5.638)
  114. Su X, Li T, Liu Z, Huang Q, Liao K, Ren R, Lu L, Qi X, Wang M, Chen J, Zhou H, Leung EL, Pan HD, Liu J, Wang H, Huang L, Liu L. Licochalcone A activates Keap1-Nrf2 signaling to suppress arthritis via phosphorylation of p62 at serine 349. Free Radic Biol Med 2018;115:471-483. (IF=6.02)
  115. Liu XY, Yang KY, Wang MQ, Kwok JS, Zeng X, Yang Z, Xiao XJ, Lau CP, Li Y, Huang ZM, Ba JG, Yim AK, Ouyang CY, Ngai SM, Chan TF, Leung EL, Liu L, Liu ZG, Tsui SKW. High-quality assembly of Dermatophagoides pteronyssinus genome and transcriptome reveals a wide range of novel allergens. J Allergy Clin Immunol 2018;2 (17):33013-33010. (IF=13.258)
  116. Fan XX#, Leung EL#, Xie Y, Liu ZQ, Zheng YF, Yao XJ, Lu LL, Wu JL, He JX, Yuan ZW, Fu JJ, Wei CL, Huang J, Xiao DK, Luo LX, Jiang ZB, Zhou YL, Kam RK, Liu L. Suppression of Lipogenesis via Reactive Oxygen Species-AMPK Signaling for Treating Malignant and Proliferative Diseases. Antioxid Redox Signal 2018;28 (5):339-357. (Selected as cover story) (IF=6.53)
  117. Dai X, Li GP, Yang XQ, Wang XY, Wu J, Leung EL*. Effects of Lyn kinase on EGFR signaling pathway in lung adenocarcinoma. China Oncology 2018, 28(01): 9-16.
  118. Zong XX, Yan G Y, Wu JL, Leung EL, Zhou H, Li N, Liu L. New C 19 -diterpenoid alkaloids from the parent roots of Aconitum carmichaelii. Tetrahedron Lett 2017;58 (16):1622-1626. (IF=2.193)
  119. Zhou H, Liu JX, Luo JF, Cheng CS, Leung EL, Li Y, Su XH, Liu ZQ, Chen TB, Duan FG, Dong Y, Zuo YH, Li C, Lio CK, Li T, Luo P, Xie Y, Yao XJ, Wang PX, Liu L. Suppressing mPGES-1 expression by sinomenine ameliorates inflammation and arthritis. Biochem Pharmacol 2017;142:133-144. (IF=4.581)
  120. Yang N, Leung EL, Liu CB, Li L, Eguether T, Yao XJ, Jones E, Norris D, Liu A, Clark R, Roop DR, Pazour GJ, Shroyer KR, Chen J. INTU is essential for oncogenic Hh signaling through regulating primary cilia formation in basal cell carcinoma. Oncogene 2017;36 (35):4997-5005. (IF=7.519)
  121. Xie C, Li LL, Fan XX, Li Y, Wei CL, Liu L*, Leung EL*, Yao XJ*. Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells. Front Pharmacol 2017;8:823. (IF=4.4)
  122. Wong VKW, Zeng W, Chen J, Yao XJ, Leung EL, Wang QQ, Chiu P, Ko BCB, Law BYK. Tetrandrine, an Activator of Autophagy, Induces Autophagic Cell Death via PKC-alpha Inhibition and mTOR-Dependent Mechanisms. Front Pharmacol 2017;8:351. (IF=4.4)
  123. Wang QQ, Li Y, Xu JH, Wang YW, Leung EL*, Liu L*, Yao XJ*. Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations. Sci Rep 2017;7 (1):8857. (IF=4.259)
  124. Pinz K, Yakaboski E, Jares A, Liu H, Firor A, Chen K, Wada M, Salman H, Tse W, Hagag N, Lan FS, Leung EL, Jiang S, Ma YP. Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells. Oncotarget 2017;8 (68):112783-112796. (IF=5.168)
  125. Petrov J, Wada M, Pinz K, Yan L, Chen K, Chen X, Liu H, Shuai X, Leung EL, Salman H, Hagag H, Liu F, Jiang X , Ma YP. Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia. Leukemia 2018 Feb 25. doi: 10.1038/s41375-018-0075-3. [Epub ahead of print] (IF=11.702)
  126. Luo LX, Li Y, Niu YZ, Fan XX, Xu JH, Liu L*, Leung EL*, Yao XJ*. Identification of a potent kinase inhibitor targeting ALK fusion proteins in non-small cell lung cancer. Med Chem Comm 2017 (IF=2.608)
  127. Luo LX, Li Y, Liu ZQ, Fan XX, Duan FG, Li RZ, Yao XJ*, EL* Leung, Liu L* . Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells. Front Pharmacol 2017;8:199. (IF=4.4)
  128. Luo LX, Fan XX, Li Y, Peng X, Ji YC, Hsiao WW, Liu L*, Leung EL*, XJ* Yao. Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells. Med Chem Commun 2017;8 (3):621-624. (IF=2.608)
  129. Lu LL, Lv SD, Ji L, Chen B, Liu S, Lei C, Liu X, Qi X, Wang Y, Leung EL, Wang H, Zhang L, Yu X, Liu ZQ, Wei Q. Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4. Oncogene 2017 (IF=7.519)
  130. Li Y#, Leung EL#, Pan HD, Yao XJ, Huang QC, Wu M, Xu T, Wang YW, Cai J, Li RZ, W Liu, Liu L. Identification of potential genetic causal variants for rheumatoid arthritis by whole-exome sequencing. Oncotarget 2017;8 (67):111119-111129. (IF=5.168)
  131. Li XG, Tang S, Wang QQ, Leung EL, Jin HY, Huang YZ, Liu J, Geng MY, Huang M, Yuan ST, Yao XJ, Ding J. Identification of Epigallocatechin-3- Gallate as an Inhibitor of Phosphoglycerate Mutase 1. Front Pharmacol 2017;8:325. (IF=4.4)
  132. Li X, Fan XX, Jiang ZB, Loo WTY, Yao XJ, Leung EL*, Chow LWC*, Liu L*. Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway. Pharmacol Res 2017;115:45-55. (Highly cited paper of the year in Elsevier) (IF=4.48)
  133. Leung EL*, E Clementi, Wong FW. Advanced technologies charting a new path for traditional Chinese medicine drug discovery. Pharmacol Res 2017;117:65-66. (IF=4.48)
  134. Law BY, Gordillo-Martínez F, Qu YQ, Zhang N, Xu SW, Saul Coghi P, Mok SW, Guo JR, Zhang W, Leung EL, Fan XX, Wu AG, Chan WK, Yao XJ, Wang JR, Liu L, Wong VK. Thalidezine, a novel AMPK activator, eliminates apoptosis-resistant cancer cells through energy-mediated autophagic cell death. Oncotarget 2017;8 (18):30077-30091. (IF=5.168)
  135. Chen X, Xie C, Fan XX, Jiang ZB, Wong VKB, Xu JH, Yao XJ*, Liu L*, Leung EL*. Novel direct AMPK activator suppresses non-small cell lung cancer through inhibition of lipid metabolism. Oncotarget 2017;8 (56):96089-96102. (IF=5.168)
  136. Chen K, Wada M, Pinz K, Liu H, Shuai X, Chen X, Yan LL, Petrov J, Salman H, Senzel L, Leung EL, Jiang X, Ma YP. A compound chimeric antigen receptor strategy for targeting multiple myeloma. Leukemia 2018 Feb;32(2):402-412. doi: 10.1038/leu.2017.302. Epub 2017 Sep 27. (IF=10.023)
  137. Chen K, Wada M, Pinz K, Liu H, Lin KW, Jares A, Firor A, Shuai X, Salman H, Golightly M, Lan FS, Senzel L, Leung EL, X Jiang, Ma YP. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia 2017;31 (10):2151-2160. (IF=11.702)
  138. Zhang YZ#, Chen X#, Fan XX, He JX, Huang J, Xiao DK, Zhou YL, Zheng SY, Xu JH, Yao XJ, Liu L*, Leung EL*. Compound Library Screening Identified Cardiac Glycoside Digitoxin as an Effective Growth Inhibitor of Gefitinib-Resistant Non-Small Cell Lung Cancer via Downregulation of alpha-Tubulin and Inhibition of Microtubule Formation. Molecules 2016;21 (3):374. (IF=2.465)
  139. Yu J, Zhang Y, Leung LH, Liu L, Yang F, Yao XJ. Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis. J Hematol Oncol 2016;9 (1):111. (IF=6.263)
  140. Xu SW, Law BY, Mok SW, Leung EL, Fan XX, Coghi PS, Zeng W, Leung CH, Ma DL, Liu L, Wong VKB. Autophagic degradation of epidermal growth factor receptor in gefitinib-resistant lung cancer by celastrol. Int J Oncol 2016;49 (4):1576-1588. (IF=3.018)
  141. Wong VK#, Law YK#, Yao XJ, Chen X, Xu SW, Liu L*, Leung EL*. Advanced research technology for discovery of new effective compounds from Chinese herbal medicine and their molecular targets. Pharmacol Res 2016;111:546-555. (IF=4.816)
  142. Wong VK, Dong H, Liang X, Bai LP, Jiang ZH, Guo Y, Kong AN, Wang R, Kam RK, Law BY, Hsiao WW, Chan KM, Wang J, Chan RW, Guo J, Zhang W, Yen FG, Zhou H, Leung EL, Yu Z, Liu L. Rh2E2, a novel metabolic suppressor, specifically inhibits energy-based metabolism of tumor cells. Oncotarget 2016;7 (9):9907-9924. (IF=5.008)
  143. Wang MF#, Li RZ#, Li Y, Cheng XQ, Yang J, Chen W, Fan XX, Pan HD, Yao XJ, RT XQ, Liu L*, Leung EL*, Tang YJ*. Clinical statistics analysis on the characteristics of pneumoconiosis of Chinese miner population. J Thorac Dis 2016;8 (8):2203-2211. (IF=1.649)
  144. Liang Y, Wu JL, Li X, Guo MQ, Leung EL, Zhou H, Liu L, Li N. Anti-cancer and anti-inflammatory new vakognavine-type alkaloid from the roots of Aconitum carmichaelii. Tetrahedron Lett 2016;57 (52):5881-5884. (IF=2.347)
  145. Liang Y, Wu JL, Leung EL, Zhou H, Liu ZQ, Yan GY, Liu Y, Liu L*, Li N*. Identification of Oxygenated Fatty Acid as a Side Chain of Lipo-Alkaloids in Aconitum carmichaelii by UHPLC-Q-TOF-MS and a Database. Molecules 2016;21 (4):437. (IF=2.465)
  146. Leung EL, Fan XX, Wong MP, Jiang ZH, Liu ZQ, Yao XJ, Lu LL, Zhou YL, Yau LF, Tin PC, Liu L. Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation. Antioxid Redox Signal 2016;24 (5):263-279. (Selected as cover story) (IF=7.093)
  147. Jiang ZB#, Huang J#, Xie C, Li X, Liu L, He J, Pan H, Huang L, Fan XX, Yao XJ, Xie Y, Li N, Liu L, He JX*, Leung EL*. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations. Oncolo Rep 2016;36 (1):365-375. (IF=2.486)
  148. Huang J#, Fan XX#, He JX, Pan H, Li RZ, Huang LY, Jiang ZB, Yao XJ, Liu L, Leung EL*, He JX*. SCD1 is associated with tumor promotion, late stage and poor survival in lung adenocarcinoma. Oncotarget 2016;7 (26):39970-39979. (IF=5.008)
  149. Chan CM, Chu H, Zhang AJ, Leung EL, Sze KH, Kao RY, Chik KK, To KK, Chan JW, Chen H, Jin DY, L Liu, Yuen KY*. Hemagglutinin of influenza A virus binds specifically to cell surface nucleolin and plays a role in virus internalization. Virology 2016;494:78-88. (IF=3.2)
  150. Yuan ZW, Leung EL, Fan XX, Ma WZ, Liu L, Xie Y. Quantitative evaluation of berberine subcellular distribution and cellular accumulation in non-small cell lung cancer cells by UPLC-MS/MS. Talanta 2015;144:20-28. (IF= 3.545)
  151. Yang ZF#, Leung EL#, Liu L, ZH Jiang, Zhong NS*. Developing influenza treatments using traditional Chinese medicine. Science 2015;347 (6219):S35-S37. (IF= 33.611)
  152. Wang R, Zhang CY, Bai LP, Pan HD, Shu LM, Kong AN, Leung EL, Liu L, Li T. Flavonoids derived from liquorice suppress murine macrophage activation by up-regulating heme oxygenase-1 independent of Nrf2 activation. Int Immunopharmacol 2015;28 (2):917-924. (IF= 2.472)
  153. Lu LL, Liu XH, Leung EL, Wang Y, Shi J, Hu M, Liu L, Liu ZQ. The bioavailability barrier and personalized traditional Chinese medicine. Science 2015;350 (6262):S79-S81. (IF= 33.611)
  154. Liu L, Liu L, Leung EL, Cooney AJ, Chen C, Rosengart TK, Ma YP, Yang JC. Knockdown of SALL4 Protein Enhances All-trans Retinoic Acid-induced Cellular Differentiation in Acute Myeloid Leukemia Cells. J Biol Chem 2015;290 (17):10599-10609. (IF= 2.472)
  155. Li T, Wong VK, Jiang ZH, Jiang SP, Liu Y, Wang TY, Yao XJ, Su XH, Yan FG, Liu J, Leung EL, Yi XQ, Wong YF, Zhou H, Liu L. Mutation of cysteine 46 in IKK-beta increases inflammatory responses. Oncotarget 2015;6 (31):31805-31819. (IF= 6.359)
  156. Gu WY, Li N*, Leung EL, Zhou H, Luo GA, L Liu, Wu JL*. Metabolites software-assisted flavonoid hunting in plants using ultra-high performance liquid chromatography-quadrupole-time of flight mass spectrometry. Molecules 2015;20 (3):3955-3971. (IF= 2.416)
  157. Gu WY, Li N, Leung EL, Zhou H, Yao XJ, Liu L, Wu JL. Rapid identification of new minor chemical constituents from Smilacis Glabrae Rhizoma by combined use of UHPLC-Q-TOF-MS, preparative HPLC and UHPLC-SPE-NMR-MS techniques. Phytochem Anal 2015;26 (6):428-435. (IF=2.341)
  158. Fan XX, Yao XJ, Xu SW, Wong VKW, He JX, Ding J, Xue WW, Mujtaba T, Michelangeli F, Huang M, Huang J, Xiao DK, Jiang ZB, Zhou YL, Kam R.K., Liu L*, Leung EL*. (Z)3,4,5,4′-trans-tetramethoxystilbene, a new analogue of resveratrol, inhibits gefitinb-resistant non-small cell lung cancer via selectively elevating intracellular calcium level. Sci Rep 2015;5:16348. (IF= 5.578)
  159. Leung EL, Wong VK, Jiang ZH, T Li, Liu L*. Integrated network-based medicine: The role of traditional Chinese medicine in developing a new generation of medicine. Science 2014;346 (6216):S16-17. (IF=31.477)
  160. Fan XX, Li N, Wu JL, Zhou YL, He JX, Liu L, Leung EL*. Celastrol induces apoptosis in gefitinib-resistant non-small cell lung cancer cells via caspases-dependent pathways and Hsp90 client protein degradation. Molecules 2014;19 (3):3508-3522. (IF=2.095)
  161. Wu JL, Leung EL, Zhou H, L Liu, Li N. Metabolite analysis of toosendanin by an ultra-high performance liquid chromatography-quadrupole-time of flight mass spectrometry technique. Molecules 2013;18 (10):12144-12153. (IF=2.428)
  162. Wang TY, Zhou H, Wong YF, Wu PK, Hsiao WL, Leung EL, Liu L. The Predicted Proteomic Network Associated with the Antiarthritic Action of Qingfu Guanjieshu in Collagen-II-Induced Arthritis in Rats. Evid Based Complement Alternat Med 2013;2013:582493. (IF=1.722)
  163. Leung EL, Cao ZW, Jiang ZH, Zhou H, Liu L. Network-based drug discovery by integrating systems biology and computational technologies. Brief Bioinform 2013;14 (4):491-505. (IF=5.298)
  164. Wong DW, Leung EL, Wong SK, Tin VP, Sihoe AD, Cheng LC, Au JS, Chung LP, Wong MP. A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer 2011;117 (12):2709-2718. (IF=5.131)
  165. Liu L, Leung ELH, Tian XY. PERSPECTIVE The clinical trial barriers. Nature 2011;480 (7378):S100-S100. (IF=36.104)
  166. Leung EL, Wong JC, Johlfs MG, Tsang BK, Fiscus RR. Protein kinase G type Ialpha activity in human ovarian cancer cells significantly contributes to enhanced Src activation and DNA synthesis/cell proliferation . Mol Cancer Res 2010;8 (4):578-591. (IF=4.162)
  167. Leung EL, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe AD, Fink LM, Ma Y, Wong MP. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One 2010;5 (11):0014062. (IF=4.351)
  168. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, Ho KK, Au JS, Chung LP, Pik Wong M. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115 (8):1723-1733. (IF=5.238)
  169. Tam IY, Leung EL, Tin VP, Chua DT, Sihoe AD, Cheng LC, Chung LP, Wong MP. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther 2009;8 (8):2142-2151. (IF=5.003)
  170. Leung EL, Tam IY, Tin VP, Chua DT, Sihoe AD, Cheng LC, Ho JC, Chung LP, Wong MP. SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy. Mol Cancer Res 2009;7 (6):923-932. (IF=4.533)
  171. Gai H, Leung EL, Costantino PD, Aguila JR, Nguyen DM, Fink LM, Ward DC, Ma Y. Generation and characterization of functional cardiomyocytes using induced pluripotent stem cells derived from human fibroblasts. Cell biology international 2009;33 (11):1184-1193. (IF=1.619)
  172. Leung EL, Fraser M, Fiscus RR, Tsang BK. Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance. Br J Cancer 2008;98 (11):1803-1809. (IF=4.635)